Author:

Keywords:

Bromocriptine, Dopamine Agents, Ergolines, Humans, Lung Diseases, Male, Middle Aged, Parkinson Disease, Pleural Effusion, Science & Technology, Life Sciences & Biomedicine, Respiratory System, CABERGOLINE, PLEUROPULMONARY CHANGE, PARKINSONS DISEASE, BROMOCRIPTINE TREATMENT, FIBROSIS, Cabergoline, 11 Medical and Health Sciences, 3201 Cardiovascular medicine and haematology

Abstract:

A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. These lesions even worsened for some weeks after interruption of cabergoline, which may possibly be related to the prolonged action of this drug. Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.